Preclinical data demonstrated that AZD6244 has potential to inhibit tumor proliferation, induce differentiation and apoptosis activity in KRAS-mutant xenograft models and that antitumor efficacy was improved by combining with cytotoxic drugs as docetaxel [108]. Here, KRAS is linked to neoplasm.